Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Required: CD19 positive

Participants who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy

Required: HIV1 positive

Documentation of HIV-1 infection by means of any one of the following: ... (see protocol for details)

Required: HIV1 viral load <50 copies/mL (<50 copies/mL)

HIV viral load below 50 copies/mL by FDA-approved assays within 4 weeks prior to registration

Required: HIV1 CD4 count (CD4 cell count must be obtained; minimum of 6 participants with CD4 <100 cells/uL)

A CD4 cell count must be obtained within 4 weeks before enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent. Twenty participants will be studied with a goal to enroll a minimum of 6 participants with a CD4 <100 cells/uL

Must have received: anthracycline

Participant must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have R/R disease after at least 2 lines of therapy

Must have received: CD20-targeted therapy (rituximab)

Participant must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have R/R disease after at least 2 lines of therapy

Cannot have received: alemtuzumab (alemtuzumab)

Treatment with alemtuzumab within 6 months before anticipated leukapheresis

Cannot have received: purine analog (fludarabine, cladribine)

treatment with fludarabine or cladribine within 3 months before anticipated leukapheresis

Cannot have received: CAR-T cell therapy

Prior receipt of CAR T-cell therapy